Skip to main content
Premium Trial:

Request an Annual Quote

Glaxo Wellcome, NeXstar Announce Collaboration


BOULDER, Colo.--NeXstar Pharmaceuticals here announced a three-part collaboration with Glaxo Wellcome. The agreement grants Glaxo nonexclusive use of NeXstar's proprietary Selex drug discovery process, a combinatorial chemistry technology, as a research tool for target validation in Glaxo's functional genomics program. Additionally, NeXstar will receive exclusive rights to develop and commercialize a liposomal formulation of Glaxo's proprietary topoisomerase I inhibitor, a compound that has completed phase two clinical trials for the treatment of various cancers in its nonliposomal form. Glaxo will also make a $10 million equity investment in NeXstar, purchasing 962,117 shares of NeXstar common stock for $10.39 per share.

NeXstar CEO Patrick Mahaffy said Glaxo's interest in using the Selex technology for target validation "highlights the potential for aptamers to significantly speed up and improve drug discovery and development programs." Mahaffy said his company is also enthusiastic about the opportunity to develop liposomal lurtotecan.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.